explore -WSS

explore

author：fashion 2025-10-02 22:15:44 - browse：4936

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Can sheer will power keep patients alive in their dying hours?

WSS

Medicare Advantage beneficiaries sue Humana over algorithm use

Paxlovid should be available without a positive Covid test

After a drawn out lobbying fight, ARPA

Three trends to watch in biotech in 2024

SNAP should offer more nutrition education

Hospitals owned by private equity see complications spike 25%

knowledge

explore

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Data show record exodus of life scientists from academia

Anesthesiologist group: stop taking Ozempic before surgery

Menendez indictment could see pharma lose a key ally

Psychedelics group wrestles with new pharma identity

Violet CEO on training clinicians to promote more inclusive care

After affirmative action ruling, medical educators look to 'holistic review'

After a drawn out lobbying fight, ARPA

Heart attack and stroke risk calculators need revising

HCA sued by state AG for quality issues at Mission Health

explore

What STAT readers think about the FDA and patient advocacy

WHO recommends dropping component of many flu vaccines

Albert Bourla of Pfizer: worst biopharma CEO of 2023

How one patient went off dialysis — and others can too

Health tech startups drop sharply from 2021 highs

Address the ethical violations that led to 'Three Identical Strangers'

focus

explore

focus

explore